In both in vitro and in vivo studies, NKTR-255-expanded NK cells enhanced anti-tumor cytotoxicity, suppressed tumor growth, and, when combined with the anti-CD38 antibody daratumumab, effectively inhibited multiple myeloma cells. This evidence concerns the gene CD38 and neoplasm.